Share This Page

Support & Insight for the Autumn of Life

Solanezumab May Become The 1st Alzheimer’s-Modifying Treatment

Monoclonal antibody (Source:Polygon)

Learn why neurologists wish they could prescribe experimental solanezumab to 15% of their Alzheimer’s patients. Solanezumab is Eli Lilly’s exciting, maturing attempt to create a vaccine that dissolves Alzheimer’s plaque.


Surveyed U.S. neurologists would prescribe Eli Lilly’s emerging anti-beta-amyloid monoclonal antibody solanezumab to 15% of their mild to moderate Alzheimer’s patients.

Solanezumab has been through a number of trials where it helped, though it did not meet all expectations. It is currently undergoing new and ongoing trials to fine-tune how it can help people with Alzheimer’s.

Encouraging Results

Interviewed thought leaders are encouraged by a slowing of cognitive decline observed in solanezumab-treated mild AD patients, pooled across two completed, placebo-controlled, Phase III studies, as well as the drug’s safety profile, particularly with regard to a low risk of amyloid-related imaging abnormalities.

The report also includes insights from a survey of U.S. managed care organization pharmacy directors, two-thirds of whom indicate they would reimburse a new disease-modifying therapy for the treatment of mild to moderate AD that was priced at a significant premium to current brands ($25/day), if such an agent offered a 200 percent improvement on cognitive decline over donepezil (Eisai/Pfizer’s Aricept, other brands, generics). Payers expecting not to cover such a therapy mostly cite insufficient benefits as the reason, suggesting that—for some payers—greater therapeutic gains would be needed to justify the value of a drug offered at such a considerable cost.

Filling an Unmet Need

Drugs offering a greater effect on cognition and those offering a greater effect on function compared with current treatments remain the top unmet needs in the treatment of mild to moderate Alzheimer’s disease (AD), according to surveyed U.S. and European neurologists. Currently available therapies alleviate some cognitive and functional symptoms associated with AD over the short-term, but do not slow disease progression, thus underscoring the remaining unmet need for more efficacious alternatives, which could be either symptomatic or disease-modifying.

“With a new Phase III trial ongoing in mild AD, solanezumab retains
the potential to become the first disease-modifying therapy approved for
the treatment of this debilitating disease, a landmark achievement,”
said Decision Resources Senior Business Insights Analyst Alana Simorellis,
Ph.D. “We expect solanezumab likely would be priced much higher than
symptomatic brands today, which could present challenges to usage and
market access, depending on the level of its clinical benefits. Even
with limited uptake, however, we expect premium pricing and a growing
patient population could easily drive blockbuster sales for solanezumab
in the AD market over the next decade.”


About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources GroupDecision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
 
SOURCE:
Decision Resources
Web Site: http://decisionresourcesgroup.com

Email me when people comment
Notify of
guest

This site uses Akismet to reduce spam. Learn how your comment data is processed.

0 Comments
Inline Feedbacks
View all comments
Edited by:
Picture of P. Berger

P. Berger

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. it has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Share this page To

Related:

Prevention

ADDF: What Works & What Doesn’t in Preventing Alzheimer’s

Alzheimer’s prevention and memory conservation is on everyone’s health radar. Every year, we spend billions on related supplements and alternative medicines. To sort out what might work and what doesn’t, what’s safe and what’s dangerous, and how confident experts are in the science, check out ADDF’s brain-protection website, Cognitive Vitality.

Read More »
Share to Facebook
Twitter
LinkedIn

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. it has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Visit Alzheimer's Weekly On

0
Would love your thoughts, please comment.x
()
x
News, Treatments, Care Tips, Diet

Alzheimer's & Dementia Weekly Newsletter: Free

Free. Care & Treatment. Research & Prevention

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. It has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

News to Get at the Truth

Subscribe To Our Weekly Newsletter